{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:16:47Z","timestamp":1784791007704,"version":"3.55.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-AI052071"],"award-info":[{"award-number":["T32-AI052071"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Limited data are available to guide effective antibiotic durations for hospitalized patients with complicated urinary tract infections (cUTIs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted an observational study of patients \u226518 years at 24 US hospitals to identify the optimal treatment duration for patients with cUTI. To increase the likelihood patients experienced true infection, eligibility was limited to those with associated bacteremia. Propensity scores were generated for an inverse probability of treatment weighted analysis. The primary outcome was recurrent infection with the same species \u226430 days of completing therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>1099 patients met eligibility criteria and received 7 (n = 265), 10 (n = 382), or 14 (n = 452) days of therapy. There was no difference in the odds of recurrent infection for patients receiving 10 days and those receiving 14 days of therapy (aOR: .99; 95% CI: .52\u20131.87). Increased odds of recurrence was observed in patients receiving 7 days versus 14 days of treatment (aOR: 2.54; 95% CI: 1.40\u20134.60). When limiting the 7-day versus 14-day analysis to the 627 patients who remained on intravenous beta-lactam therapy or were transitioned to highly bioavailable oral agents, differences in outcomes no longer persisted (aOR: .76; 95% CI: .38\u20131.52). Of 76 patients with recurrent infections, 2 (11%), 2 (10%), and 10 (36%) in the 7-, 10-, and 14-day groups, respectively, had drug-resistant infections (P = .10).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Seven days of antibiotics appears effective for hospitalized patients with cUTI when antibiotics with comparable intravenous and oral bioavailability are administered; 10 days may be needed for all other patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad009","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T19:42:55Z","timestamp":1673552575000},"page":"1604-1612","source":"Crossref","is-referenced-by-count":53,"title":["Defining the Optimal Duration of Therapy for Hospitalized Patients With Complicated Urinary Tract Infections and Associated Bacteremia"],"prefix":"10.1093","volume":"76","author":[{"given":"John","family":"McAteer","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hyoung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Dzintars","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Johns Hopkins Hospital , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suiyini","family":"Fiawoo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily L","family":"Heil","sequence":"additional","affiliation":[{"name":"Department of Practice, Science, and Health Outcomes Research, University of Maryland School of Pharmacy , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald E","family":"Kendall","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Veterans Affairs Ann Arbor Healthcare System , Ann Arbor, Michigan , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Louie","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Rochester School of Medicine and Dentistry , Rochester, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag N","family":"Malani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Trinity Health St. Joseph Mercy , Ann Arbor, Michigan , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Nori","sequence":"additional","affiliation":[{"name":"Department of Medicine, Albert Einstein College of Medicine , Bronx, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M","family":"Percival","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, University of Iowa Hospitals & Clinics , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4143-6324","authenticated-orcid":false,"given":"Pranita D","family":"Tamma","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"2023080918565599300_ciad009-B1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"2023080918565599300_ciad009-B2"},{"key":"2023080918565599300_ciad009-B3","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jsps.2018.02.023","article-title":"Risk factors for acquiring multidrug-resistant organisms in urinary tract infections: a systematic literature review","volume":"26","author":"Tenney","year":"2018","journal-title":"Saudi Pharm J"},{"key":"2023080918565599300_ciad009-B4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jama.2021.9899","article-title":"Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract infection: a randomized clinical trial","volume":"326","author":"Drekonja","year":"2021","journal-title":"JAMA"},{"key":"2023080918565599300_ciad009-B5","doi-asserted-by":"crossref","first-page":"ofab434","DOI":"10.1093\/ofid\/ofab434","article-title":"Optimizing the management of uncomplicated gram-negative bloodstream infections: consensus guidance using a modified Delphi process","volume":"8","author":"Heil","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023080918565599300_ciad009-B6","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/EDE.0b013e3181577654","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"18","author":"von Elm","year":"2007","journal-title":"Epidemiology"},{"key":"2023080918565599300_ciad009-B7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum beta-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023080918565599300_ciad009-B8","first-page":"e497","article-title":"Comparing propensity score methods versus traditional regression analysis for the evaluation of observational data: a case study evaluating the treatment of gram-negative bloodstream infections","volume":"71","author":"Amoah","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023080918565599300_ciad009-B9","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial","volume":"69","author":"Yahav","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023080918565599300_ciad009-B10","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA"},{"key":"2023080918565599300_ciad009-B11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cmi.2021.09.001","article-title":"Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial","volume":"28","author":"Molina","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023080918565599300_ciad009-B12","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1056\/NEJMoa1411162","article-title":"Trial of short-course antimicrobial therapy for intraabdominal infection","volume":"372","author":"Sawyer","year":"2015","journal-title":"N Engl J Med"},{"key":"2023080918565599300_ciad009-B13","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1185\/030079907X233340","article-title":"A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and\/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis","volume":"23","author":"Klausner","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"2023080918565599300_ciad009-B14","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s10096-017-2951-6","article-title":"Is 5 days of oral fluoroquinolone enough for acute uncomplicated pyelonephritis? The DTP randomized trial","volume":"36","author":"Dinh","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023080918565599300_ciad009-B15","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"key":"2023080918565599300_ciad009-B16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)60608-4","article-title":"Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial","volume":"380","author":"Sandberg","year":"2012","journal-title":"Lancet"},{"key":"2023080918565599300_ciad009-B17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"Peterson","year":"2008","journal-title":"Urology"},{"key":"2023080918565599300_ciad009-B18","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","article-title":"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial","volume":"290","author":"Chastre","year":"2003","journal-title":"JAMA"},{"key":"2023080918565599300_ciad009-B19","doi-asserted-by":"crossref","first-page":"e41290","DOI":"10.1371\/journal.pone.0041290","article-title":"Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment","volume":"7","author":"Capellier","year":"2012","journal-title":"PLoS One"},{"key":"2023080918565599300_ciad009-B20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/0036554021000026988","article-title":"Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up","volume":"35","author":"Ulleryd","year":"2003","journal-title":"Scand J Infect Dis"},{"key":"2023080918565599300_ciad009-B21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12916-017-0835-3","article-title":"Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women","volume":"15","author":"van Nieuwkoop","year":"2017","journal-title":"BMC Med"},{"key":"2023080918565599300_ciad009-B22","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1086\/423000","article-title":"A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury","volume":"39","author":"Dow","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2023080918565599300_ciad009-B23","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1128\/AAC.41.10.2256","article-title":"Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses","volume":"41","author":"Chien","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080918565599300_ciad009-B24","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1128\/AAC.36.5.993","article-title":"Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses","volume":"36","author":"Lettieri","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080918565599300_ciad009-B25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1128\/AAC.39.1.28","article-title":"Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients","volume":"39","author":"Chin","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080918565599300_ciad009-B26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.293.8.949","article-title":"Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial","volume":"293","author":"Hooton","year":"2005","journal-title":"JAMA"},{"key":"2023080918565599300_ciad009-B27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/00365540110080728","article-title":"Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women","volume":"34","author":"Nicolle","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"2023080918565599300_ciad009-B28","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy297","article-title":"Antimicrobial susceptibility trends observed in urinary pathogens obtained from New York state","volume":"5","author":"Rank","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2023080918565599300_ciad009-B29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02313-16","article-title":"Application of fluoroquinolone resistance score in management of complicated urinary tract infections","volume":"61","author":"Shah","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080918565599300_ciad009-B30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01317-17","article-title":"A cohort study of risk factors that influence empirical treatment of patients with acute pyelonephritis","volume":"61","author":"Bosch-Nicolau","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080918565599300_ciad009-B31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijid.2013.12.021","article-title":"Factors associated with ciprofloxacin- and cefotaxime-resistant Escherichia coli in women with acute pyelonephritis in the emergency department","volume":"23","author":"Park","year":"2014","journal-title":"Int J Infect Dis"},{"key":"2023080918565599300_ciad009-B32","doi-asserted-by":"crossref","first-page":"i939","DOI":"10.1136\/bmj.i939","article-title":"Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis","volume":"352","author":"Bryce","year":"2016","journal-title":"BMJ"},{"key":"2023080918565599300_ciad009-B33","author":"Food and Drug Administration"},{"key":"2023080918565599300_ciad009-B34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.18773\/austprescr.2021.035","article-title":"Fluoroquinolone antibiotics and adverse events","volume":"44","author":"Baggio","year":"2021","journal-title":"Aust Prescr"},{"key":"2023080918565599300_ciad009-B35","doi-asserted-by":"crossref","first-page":"a816","DOI":"10.1136\/bmj.a816","article-title":"FDA adds \u201cblack box\u201d warning label to fluoroquinolone antibiotics","volume":"337","author":"Tanne","year":"2008","journal-title":"BMJ"},{"key":"2023080918565599300_ciad009-B36","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/cid\/ciab637","article-title":"Association of adverse events with antibiotic treatment for urinary tract infection","volume":"74","author":"Butler","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023080918565599300_ciad009-B37","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jamainternmed.2017.1938","article-title":"Association of adverse events with antibiotic use in hospitalized patients","volume":"177","author":"Tamma","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2023080918565599300_ciad009-B38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ajic.2018.09.020","article-title":"Hazards from physical attributes of the home environment among patients on outpatient parenteral antimicrobial therapy","volume":"47","author":"Keller","year":"2019","journal-title":"Am J Infect Control"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad009\/49232952\/ciad009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/9\/1604\/51077809\/ciad009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/9\/1604\/51077809\/ciad009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T18:57:20Z","timestamp":1691607440000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/9\/1604\/6986293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,1,12]]},"published-print":{"date-parts":[[2023,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad009","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,1,12]]}}}